Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth
factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer …

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the
impressive improvement of treatments observed over the last 20 years that led to an …

Background The KRAS mutation is not responsible for all cases of resistance to anti–
epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new …

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have
improved outcomes for patients with metastatic colorectal carcinoma. Among patients not …

Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with
chemotherapy is effective for patients with RAS wild type metastatic colorectal cancer …

The epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal
roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two …

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and
panitumumab is the main targeted treatment to combine with standard chemotherapy for …

The introduction of new cytotoxic agents and new targeted therapies has significantly
broadened the therapeutic options for and the outcomes of patients with metastatic …